Literature DB >> 19151247

Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine.

S S Negus1, M H Baumann, R B Rothman, N K Mello, B E Blough.   

Abstract

Monoamine releasers constitute one class of drugs currently under investigation as potential agonist medications for the treatment of cocaine dependence. The efficacy and safety of monoamine releasers as candidate medications may be influenced in part by their relative potency to release dopamine and serotonin, and we reported previously that releasers with approximately 30-fold selectivity for dopamine versus serotonin release may be especially promising. The present study examined the effects of the releasers benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine, which have 20- to 48-fold selectivity in vitro for releasing dopamine versus serotonin. In an assay of cocaine discrimination, rhesus monkeys were trained to discriminate 0.4 mg/kg i.m. cocaine from saline in a two-key, food-reinforced procedure. Each of the releasers produced a dose- and time-dependent substitution for cocaine. 4-Benzylpiperidine had the most rapid onset and shortest duration of action. Phenmetrazine and benzylpiperazine had slower onsets and longer durations of action. In an assay of cocaine self-administration, rhesus monkeys were trained to respond for cocaine injections and food pellets under a second order schedule. Treatment for 7 days with each of the releasers produced a dose-dependent and selective reduction in self-administration of cocaine (0.01 mg/kg/injection). The most selective effects were produced by phenmetrazine. Phenmetrazine also produced a downward shift in the cocaine self-administration dose effect curve, virtually eliminating responding maintained by a 30-fold range of cocaine doses (0.0032-0.1 mg/kg/injection) while having only small and transient effects on food-maintained responding. These findings support the potential utility of dopamine-selective releasers as candidate treatments for cocaine dependence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19151247      PMCID: PMC2670586          DOI: 10.1124/jpet.108.143701

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  Pharmacotherapy and other treatments for cocaine abuse and dependence.

Authors:  Frank J Vocci; Ahmed Elkashef
Journal:  Curr Opin Psychiatry       Date:  2005-05       Impact factor: 4.741

Review 2.  Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.

Authors:  John Grabowski; James Shearer; John Merrill; S Stevens Negus
Journal:  Addict Behav       Date:  2004-09       Impact factor: 3.913

3.  Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys.

Authors:  Nancy K Mello; S Stevens Negus; Kenner C Rice; Jack H Mendelson
Journal:  Pharmacol Biochem Behav       Date:  2006-12-19       Impact factor: 3.533

4.  Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys.

Authors:  S S Negus; N K Mello; X Lamas; J H Mendelson
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

5.  Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys.

Authors:  S Stevens Negus; Nancy K Mello
Journal:  Drug Alcohol Depend       Date:  2003-05-01       Impact factor: 4.492

Review 6.  Neurochemical mechanisms involved in behavioral effects of amphetamines and related designer drugs.

Authors:  L H Gold; M A Geyer; G F Koob
Journal:  NIDA Res Monogr       Date:  1989

7.  Comparison of behavior maintained by infusions of eight phenylethylamines in baboons.

Authors:  R R Griffiths; G Winger; J V Brady; J D Snell
Journal:  Psychopharmacology (Berl)       Date:  1976-11-24       Impact factor: 4.530

8.  Reinforcing and subjective effects of several anorectics in normal human volunteers.

Authors:  L D Chait; E H Uhlenhuth; C E Johanson
Journal:  J Pharmacol Exp Ther       Date:  1987-09       Impact factor: 4.030

9.  Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans.

Authors:  M H Baumann; R B Rothman
Journal:  Biol Psychiatry       Date:  1998-10-01       Impact factor: 13.382

10.  Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers.

Authors:  D R Jasinski; S Krishnan
Journal:  J Psychopharmacol       Date:  2008-07-17       Impact factor: 4.153

View more
  24 in total

Review 1.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

2.  Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys.

Authors:  Jessica McClung; William Fantegrossi; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2010-03-23       Impact factor: 4.530

Review 3.  Agonist replacement therapy for cocaine dependence: a translational review.

Authors:  Craig R Rush; William W Stoops
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

4.  The individual and combined effects of phenmetrazine and mgluR2/3 agonist LY379268 on the motivation to self-administer cocaine.

Authors:  Anushree N Karkhanis; Thomas J R Beveridge; Bruce E Blough; Sara R Jones; Mark J Ferris
Journal:  Drug Alcohol Depend       Date:  2016-06-25       Impact factor: 4.492

5.  Effects of monoamine releasers with varying selectivity for releasing dopamine/norepinephrine versus serotonin on choice between cocaine and food in rhesus monkeys.

Authors:  Matthew L Banks; Bruce E Blough; S Stevens Negus
Journal:  Behav Pharmacol       Date:  2011-12       Impact factor: 2.293

Review 6.  Agonist Medications for the Treatment of Cocaine Use Disorder.

Authors:  S Stevens Negus; Jack Henningfield
Journal:  Neuropsychopharmacology       Date:  2014-12-11       Impact factor: 7.853

7.  Interaction between behavioral and pharmacological treatment strategies to decrease cocaine choice in rhesus monkeys.

Authors:  Matthew L Banks; Bruce E Blough; S Stevens Negus
Journal:  Neuropsychopharmacology       Date:  2012-09-21       Impact factor: 7.853

8.  Skin Delivery and Irritation Potential of Phenmetrazine as a Candidate Transdermal Formulation for Repurposed Indications.

Authors:  Ying Jiang; Kevin S Murnane; Sonalika A Bhattaccharjee; Bruce E Blough; Ajay K Banga
Journal:  AAPS J       Date:  2019-05-31       Impact factor: 4.009

9.  Cocaine self-administration produces pharmacodynamic tolerance: differential effects on the potency of dopamine transporter blockers, releasers, and methylphenidate.

Authors:  Mark J Ferris; Erin S Calipari; Yolanda Mateo; James R Melchior; David C S Roberts; Sara R Jones
Journal:  Neuropsychopharmacology       Date:  2012-03-07       Impact factor: 7.853

10.  Role of phenmetrazine as an active metabolite of phendimetrazine: evidence from studies of drug discrimination and pharmacokinetics in rhesus monkeys.

Authors:  Matthew L Banks; Bruce E Blough; Timothy R Fennell; Rodney W Snyder; S Stevens Negus
Journal:  Drug Alcohol Depend       Date:  2012-12-01       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.